Loading...

Preclinical evaluation of 188 Re-HYNIC-PSMA as a novel therapeutic agent

Hadisi, M ; Sharif University of Technology | 2022

35 Viewed
  1. Type of Document: Article
  2. DOI: 10.1007/s10967-021-08173-1
  3. Publisher: Springer Science and Business Media B.V , 2022
  4. Abstract:
  5. In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. 188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed. © 2022, Akadémiai Kiadó, Budapest, Hungary
  6. Keywords:
  7. PSMA ; Radiolabeled compound ; Rhenium-188 ; Therapy ; Prostate specific membrane antigen ; Rhenium 186 ; Animal experiment ; Animal tissue ; Blood sampling ; Cell function ; Distribution parameters ; High performance liquid chromatography ; Human ; Human cell ; Male ; Nonhuman ; Patient care ; Preclinical study ; Process optimization ; Prostate tumor ; Quality control ; Radiochemistry ; Radiolabeling ; Rat ; Thin layer chromatography
  8. Source: Journal of Radioanalytical and Nuclear Chemistry ; Volume 331, Issue 2 , 2022 , Pages 841-849 ; 02365731 (ISSN)
  9. URL: https://link.springer.com/article/10.1007/s10967-021-08173-1